The MDS Foundation proudly partners with the following organizations
Every gift helps patients, caregivers, and healthcare professionals access life-saving resources, support, and education. Together, we can make a difference. Even a small contribution can create a big impact. Thank you for your generosity.
The MDS Foundation proudly partners with the following organizations
Phone within the US
1-(800)-637-0839Outside the US only
1-609-298-1035Address
The MDS Foundation
228 Park Ave S
PMB 118983
New York
NY 10003-1502
The MDS Foundation is a global nonprofit 501(c)(3) advocacy organization (EIN 22-3283911), supporting patients, families, and healthcare providers in the fields of MDS and related diseases for over 30 years.
© 2024 MDS Foundation. All rights reserved.
Advances in MDS
Updates on scientific research, clinical trials, and industry developments relevant to myelodysplastic syndromes.
May 28, 2025
Servier Ranked Among Top Companies Across Several Categories in 2024 PatientView Corporate Reputation of Pharma Survey
Servier announced that the company was ranked among the top companies across several categories in PatientView's 2024 Corporate Reputation of Pharma in the U.S. survey. This annual survey captures insights from more than 350 patient organizations reflecting their firsthand experiences, perceptions and familiarity with pharmaceutical companies.
May 28, 2025
Geron announced presentations at ASCO and EHA underscoring RYTELO® (imetelstat) efficacy and safety across range of LR-MDS patients; showcasing momentum of myelofibrosis program
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced presentations on RYTELO® (imetelstat) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2025 Congress. Together, the presentations reinforce the potential benefits of the first-in-class oligonucleotide telomerase inhibitor RYTELO for a range of patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia and showcase the progress Geron is making with the ongoing IMpactMF and IMproveMF trials of imetelstat in myelofibrosis (MF).
May 22, 2025
Taiho Oncology Presents Data at the 2025 American Society of Clinical Oncology Annual Meeting
Taiho Oncology announced the presentation of data at the 2025 American Society of Clinical Oncology Annual Meeting. Highlights include a potential novel, all-oral therapy for AML.
May 22, 2025
Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress
Rigel announced seven poster presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) 2025 Congress. Presentations will include supportive data for REZLIDHIA® (olutasidenib) utilization in patients with mIDH1 R/R AML.
May 19, 2025
Vor Bio to Explore Strategic Alternatives Following Clinical Program Wind-Down
Vor Bio has announced the initiation of a process to explore strategic alternatives—including a potential sale, merger, or asset licensing—amid a challenging funding environment. The company will wind down its clinical and manufacturing operations and has implemented a 95% workforce reduction while retaining a core team to support the strategic review.
May 14, 2025
Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) announced the presentation of new data on the company’s PK activators, mitapivat and tebapivat, in oral and poster presentations during the 30th European Hematology Association (EHA) Congress (EHA 2025) in Milan, Italy, June 12-15, 2025.
April 28, 2025
Faron Announces Positive Phase II Results for Bexmarilimab in Higher-Risk Myelodysplastic Syndrome
Faron Pharmaceuticals has announced positive topline results from its Phase II BEXMAB trial in treatment-resistant higher-risk myelodysplastic syndrome (HR MDS). The combination of bexmarilimab and azacitidine showed high overall response rates and continued strong tolerability. Full data has been submitted to the 2025 ASCO Annual Meeting, and preparations for a Phase III trial are underway.
April 28, 2025
Taiho Oncology to Present New Data at 2025 ASCO Annual Meeting, Including Two Oral Presentations
Taiho Oncology will showcase findings from five studies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, including two oral presentations. Highlights include data on novel therapies such as an all-oral decitabine-cedazuridine combination for AML, zipalertinib for NSCLC with EGFR exon 20 insertion mutations, and real-world studies on metastatic colorectal cancer and cholangiocarcinoma treatments.
